Stockreport

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and co [Read more]